Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer
详细信息 查看全文
- 作者：Jiahui Xu ; Deying Liu ; Huilin Niu…
- 关键词：Resveratrol ; Doxorubicin ; Drug resistance ; EMT ; PTEN/Akt
- 刊名：Journal of Experimental & Clinical Cancer Research
- 出版年：2017
- 出版时间：December 2017
- 年：2017
- 卷：36
- 期：1
- 全文大小：4603KB
- 刊物主题：Oncology; Cancer Research; Immunology; Apoptosis;
- 出版者：BioMed Central
- ISSN：1756-9966
- 卷排序：36
文摘
BackgroundGastric cancer is one of the major causes of cancer-related mortality worldwide. Most of patients presenting with inoperable gastric cancers rely on systemic chemotherapy for prolongation of survival. Doxorubicin (DOX) is one of the important agents against gastric cancer. Acquired DOX-resistance severely impedes the chemotherapeutic effect, invariably leading to poor prognosis. Resveratrol (RES) as a kind of phytoalexin has demonstrated anti-tumor functions in breast cancer and myeloid leukemia, but its function and mechanism are still unknown in gastric cancer treatment.